Pluvicto™ shows statistically significant & clinically meaningful rPFS benefit in patients with PSMA+ve metastatic CRPC December 12, 2022
PERLA Ph 2 trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in 1L mNSCLC December 12, 2022
New Data from the OPTIMA II Study Shows mDOR of 24.4 Months for UGN-102 in patients with Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer December 12, 2022
Preliminary Results from Trial of Berubicin for the Treatment of Recurrent GBM announced December 12, 2022
FAILED TRIAL: Ph 3 CONTACT-01 trial of cabozantinib + atezolizumab in IO- and chemo-treated mNSCLC patients did not meet its primary endpoint of OS December 12, 2022
U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Patients with R/R KMT2A- Rearranged (MLLr) Acute Leukemia December 12, 2022
BLA submitted to U.S. FDA for Talquetamab for the Patients with R/R Multiple Myeloma December 12, 2022
